APC8015 and Bevacizumab in Treating Patients With Prostate Cancer

NCT00027599 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

NIH

Sponsor class

Conditions

Prostate Cancer

Interventions

BIOLOGICAL: bevacizumab
BIOLOGICAL: prostatic acid phosphatase-sargramostim fusion protein
BIOLOGICAL: sipuleucel-T
BIOLOGICAL: therapeutic autologous dendritic cells
PROCEDURE: in vitro-treated peripheral blood stem cell transplantation

Sponsor

National Cancer Institute (NCI)